New drug cocktail shows promise for tough childhood cancers

NCT ID NCT05429502

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a combination of three drugs—ribociclib, topotecan, and temozolomide—in children with relapsed or refractory neuroblastoma and other solid tumors. The goal was to find a safe dose and see if the combination could shrink tumors. Only 12 children took part before the study was stopped early, so we don't yet know if this approach works well.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ribociclib (Kisqali) combined with topotecan (Hycamtin) and temozolomide (Temodar)
What this could lead to: If it works, this could offer a new treatment option for children with hard-to-treat neuroblastoma and other solid tumors.
What could go wrong: This trial was terminated early with only 12 participants, so results are very limited. The combination may cause serious side effects, and it is unclear if it will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma malignant glioma medulloblastoma neuroblastoma Recurrence rhabdoid tumor rhabdomyosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA

Contacts and locations

Locations

Cohen Children's Medical Center of New York

New Hyde Park, New York, 11040, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Novartis Investigative Site

Cologne, 50937, Germany
Novartis Investigative Site

Milan, MI, 20133, Italy
Novartis Investigative Site

Sutton, Surrey, SM2 5PT, United Kingdom
St Jude s Childrens Research Hospital

Memphis, Tennessee, 38105-2794, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.